Solera Health, ADA partner to prevent type 2 diabetes

Solera Health, a preventive care benefits manager, has partnered with the American Diabetes Association (ADA) to provide at-risk type 2 diabetes patients with access to the Diabetes Prevention Program (DPP) and Solera4Me, an online platform for diabetes management.

“At the ADA, we are focused on preventing, curing and improving the lives of all people affected by diabetes,” said Tamara Darsow, PhD, senior vice president of research and consumer programs. “By helping us connect people who are at risk for diabetes with the right DPP to help them prevent or delay the onset of type 2 diabetes, Solera is helping us achieve that mission.”

The 84 million Americans with prediabetes at risk of developing type 2 diabetes are the main target of this partnership. The current 1,500 DPP centers and virtual resources, that provide at-risk patients with the tools they need to prevent diabetes, will now be able to provide patients that completed the ADA’s Type 2Diabetes Risk test with access to Solera’s consumer site Solera4Me.

With Solera, patients are able to receive programs regarding their chronic disease management through lifestyle management programs. The site acts as a stepping stone for patients to begin their preventative program by matching patients to DPPs for improved patient outcomes and engagement.

“Solera is honored to join forces with the American Diabetes Association as both organizations have many synergies that will enhance access to the Diabetes Prevention Program,” said Brenda Schmidt, CEO of Solera Health. “By combining the Association’s influence and reach with our breadth of DPP providers and health plan reimbursement for DPP as a covered medical benefit, we can have a positive impact on delaying or preventing diabetes for a large portion of America’s population.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.